Genetic marker may predict need for aggressive ALL treatment in children

09/5/2013 | Oncology Nurse Advisor online

The presence of four or more copies of the gene RUNX1 in an abnormal chromosome 21 among children with acute lymphoblastic leukemia was associated with poor outcomes, according to a study in the Journal of Clinical Oncology. This gene amplification "helps identify patients who need more therapy than they may otherwise get," study author Dr. Stephen Hunger said.

View Full Article in:

Oncology Nurse Advisor online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA